Argenx has agreed to pay $2.2 billion for Forte Biosciences — a deal built around Forte’s phase 2 vitiligo drug. As Fierce Biotech reported, this is a major autoimmune pharmaceutical acquisition — and it matters to the celiac community for two specific reasons: argenx is one of the few companies pursuing treatments for severe celiac cases where the gluten-free diet isn’t enough, and vitiligo is a well-documented autoimmune comorbidity that affects a meaningful share of celiac patients.
This deal doesn’t put a new celiac drug on the horizon. But argenx’s trajectory as a company — and the conditions it targets — is directly relevant to patients and families waiting for options beyond strict dietary restriction.
What This Means for You
For most celiac patients, the gluten-free diet remains the only available treatment. It works well for many people. But a significant minority — estimates range from 7 to 30 percent depending on how carefully compliance is measured — continue experiencing symptoms and intestinal damage despite strict adherence. This group falls under the umbrella of non-responsive celiac disease, and a smaller subset receive a more serious diagnosis: refractory celiac disease, which has very limited treatment options.
Argenx has been one of the companies actively exploring pharmaceutical approaches for this underserved population. Their flagship drug, efgartigimod, works by reducing the circulating antibodies that drive autoimmune attacks — and celiac disease is within argenx’s stated research scope. When a company announces a $2.2 billion acquisition, it signals confidence and financial strength. That kind of institutional momentum tends to deepen existing research programs, not redirect them.
The vitiligo angle is also directly relevant for many celiac patients. Vitiligo — an autoimmune condition causing loss of skin pigmentation — occurs at higher rates among celiac patients than in the general population. People managing both conditions simultaneously are a real part of the celiac community, and a pharmaceutical company doubling down on vitiligo research could eventually benefit patients living at that intersection.
Key Takeaways
- Argenx is acquiring Forte Biosciences for $2.2 billion, primarily to add Forte’s phase 2 vitiligo drug to its pipeline.
- Argenx has been exploring pharmaceutical treatments for refractory celiac disease — the severe form where dietary restriction alone isn’t sufficient.
- Vitiligo occurs at elevated rates in celiac patients, making argenx’s expanded vitiligo program indirectly relevant to this community.
- A $2.2 billion acquisition signals argenx’s confidence in its autoimmune portfolio and its capacity to sustain long-term research programs.
- No drug from this acquisition is expected to directly treat celiac disease, but argenx’s broader autoimmune research continues.
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
How Argenx’s Lead Drug Works
Argenx’s efgartigimod (marketed as Vyvgart in approved indications) targets the neonatal Fc receptor, abbreviated FcRn. This receptor normally acts as a recycling mechanism for IgG antibodies — a class of immune proteins the body produces to identify and neutralize threats.
In autoimmune conditions, IgG antibodies misfire, targeting the body’s own tissue rather than pathogens. By blocking FcRn, efgartigimod prevents that recycling loop, causing IgG antibodies to break down faster and reducing their circulating levels substantially. The drug has already received regulatory approval for generalized myasthenia gravis (an autoimmune neuromuscular disease) and immune thrombocytopenia (a condition in which the immune system destroys platelets).
In celiac disease, IgG antibodies — particularly anti-tissue transglutaminase antibodies (anti-tTG) — are central to how physicians diagnose the condition and track immune activity. In severe cases, reducing these antibodies through FcRn blockade may help calm the immune response. Research interest has focused specifically on refractory celiac disease type 2 (RCD2) — a form where abnormal immune cells accumulate in the gut lining and persist regardless of diet. Patients with RCD2 face an elevated risk of developing enteropathy-associated T-cell lymphoma (EATL), a rare but serious intestinal cancer. For this group, treatment options remain scarce, which is why any pharmaceutical activity in the space is worth tracking.
Why Vitiligo and Celiac Share Biological Ground
Vitiligo is an autoimmune skin disease where the immune system attacks melanocytes — the cells that produce skin pigment — causing white patches to develop. On the surface, it has little to do with celiac disease. The underlying immune biology, however, overlaps considerably.
Both vitiligo and celiac disease are associated with HLA (human leukocyte antigen) gene variants — the genetic system that governs how the immune system distinguishes the body’s own cells from foreign invaders. Dysregulation in HLA-related pathways is a shared risk factor across many autoimmune conditions. Both diseases also involve overactive CD8+ T cells — a type of immune cell that, in these conditions, attacks self-tissue rather than pathogens.
Population data consistently show that people with one autoimmune condition have elevated rates of others. Studies in celiac patients have documented higher rates of vitiligo, thyroid disease, and type 1 diabetes compared to the general population. The patients argenx is targeting with a vitiligo drug and the patients they’re targeting in celiac research are not entirely separate groups — in many cases, they are the same people.
What Phase 2 Means — and Why $2.2 Billion Is a High Bet
Drug development runs in phases. Phase 1 tests safety in a small group. Phase 2 tests whether the drug actually works — does it reduce vitiligo, how much, at what dose, and what side effects appear? Phase 2 trials typically involve hundreds of patients and can span years. Success leads to phase 3 — the larger, more rigorous trials that regulators require before approving a new treatment.
Acquiring a phase 2 asset means buying into a drug that still has a long road ahead. At $2.2 billion, argenx is betting that Forte’s underlying science is strong enough to justify the investment before full phase 2 data matures. These are the bets biotech companies make when they have conviction in a biological target — and enough capital to absorb the risk if results disappoint.
For the celiac community, that confidence matters because of what it says about the broader argenx enterprise. A company spending $2.2 billion on autoimmune drug expansion is not scaling back its research programs. Refractory celiac disease is rare, but it’s scientifically tractable for a company with argenx’s tools and expertise in IgG-mediated autoimmunity.
As a parent raising a child with celiac disease, I’ve learned to follow the broader autoimmune pharmaceutical landscape — not because every deal translates directly into better options for celiac families, but because the companies willing to bet on hard autoimmune problems are the same companies building the tools patients eventually need. Argenx is one of those companies. This acquisition signals they’re not slowing down.